The Long Story Short: Optimizing choice and use of insulin needles image/jpeg

[Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)] Insulin degludec/liraglutid – nutzenbewertung gemäß § 35a SGB V [Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)] Insulin degludec/liraglutid – nutzenbewertung gemäß § 35a SGB V [Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Insulin degludec/liraglutid – nutzenbewertung gemäß § 35a SGB V. [Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 316. 2015 Final publication URL Indexing Status Subject

[Insulin degludec (addendum to Commission A15-10)] Insulin degludec (addendum zum Auftrag A15-10) [Insulin degludec (addendum to Commission A15-10)] Insulin degludec (addendum zum Auftrag A15-10) [Insulin degludec (addendum to Commission A15-10)] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Insulin degludec (addendum zum (...) Auftrag A15-10). [Insulin degludec (addendum to Commission A15-10)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 315. 2015 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Hypoglycemic Agents; Insulin, Long-Acting Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel

[Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V] Insulin degludec/liraglutid (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V [Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V] Insulin degludec/liraglutid (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V [Insulin degludec/liraglutide (new therapeutic indication): benefit assessment (...) according to §35a Social Code Book V] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Insulin degludec/liraglutid (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V. [Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und

[Insulin degludec/liraglutide (Addendum to Commission A15-15)] Insulin degludec/liraglutid (addendum zum Auftrag A15-15) [Insulin degludec/liraglutide (Addendum to Commission A15-15)] Insulin degludec/liraglutid (addendum zum Auftrag A15-15) [Insulin degludec/liraglutide (Addendum to Commission A15-15)] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation IQWiG. Insulin degludec/liraglutid (addendum zum Auftrag A15-15). [Insulin degludec/liraglutide (Addendum to Commission A15-15)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 327. 2015 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Hypoglycemic Agents; Insulin, Long-Acting Language Published German Country of organisation Germany English summary There is no English language summary available

Insulin Degludec (Tresiba, Novo Nordisk A/S) for the Treatment of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks ©Institute for Clinical and Economic Review, 2016 Insulin Degludec (Tresiba®, Novo Nordisk A/S) for the Treatment of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks Final Report March 14, 2016 Institute for Clinical and Economic Review ©Institute for Clinical and Economic Review, 2016 Page i Final Report – Insulin Degludec AUTHORS: Jeffrey A. Tice (...) Review DATE OF PUBLICATION: March 14, 2016 We would also like to thank Shanshan Liu, Elizabeth Russo, Matt Seidner, Patricia Synnott, and Karin Travers of ICER for their contributions to this report. ©Institute for Clinical and Economic Review, 2016 Page ii Final Report – Insulin Degludec About ICER The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders

Regulation of Insulin and Insulin-Like Activity in Malnourished Patients with Carcinoma Ventriculi Subjected to Total Gastrectomy and Personalized Nutritional Support Insulin and insulin-like growth factor (IGF) activities are disturbed during critical illness. Time-course changes in the concentrations of insulin, IGF-I and IGF-binding proteins (IGFBPs) were monitored in this study and their correlation with interleukin (IL)-6 was assessed in patients subjected to total gastrectomy and specific (...) nutritional regime.Patients were fed post-operatively according to the following scheme: parenteral nutrition on day 1, enteral nutrition combined with parenteral form from day 2 to 7, peroral nutrition from day 8 and full oral nutrition from day 14. Blood samples were taken periodically and the levels of IL-6, insulin, IGF-I and IGFBP-1 to -4 were determined.On day 1 post-operatively, the concentration of IL-6 reached its maximum and decreased afterwards. The concentration of insulin increased until day

Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. Previous studies assessing the effect of metformin on glycemic control in adolescents with type 1 diabetes have produced inconclusive results.To assess the efficacy and safety of metformin as an adjunct to insulin in treating overweight adolescents with type 1 diabetes.Multicenter (26 pediatric endocrinology clinics), double-blind, placebo-controlled (...) randomized clinical trial involving 140 adolescents aged 12.1 to 19.6 years (mean [SD] 15.3 [1.7] years) with mean type 1 diabetes duration 7.0 (3.3) years, mean body mass index (BMI) 94th (4) percentile, mean total daily insulin 1.1 (0.2) U/kg, and mean HbA1c 8.8% (0.7%).Randomization to receive metformin (n = 71) (≤2000 mg/d) or placebo (n = 69).Primary outcome was change in HbA1c from baseline to 26 weeks adjusted for baseline HbA1c. Secondary outcomes included change in blinded continuous glucose

[Insulin infusion pumps for diabetic patients] Bombas de infusión de insulina en pacientes diabéticos [Insulin infusion pumps for diabetic patients] Bombas de infusión de insulina en pacientes diabéticos [Insulin infusion pumps for diabetic patients] Mengarelli C, Pichon-Riviere A, Rey-Ares L, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Mengarelli C, Pichon-Riviere A, Rey-Ares L, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A. Bombas de infusión de insulina en pacientes diabéticos. [Insulin infusion pumps for diabetic patients] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 424. 2015 Authors' objectives To assess the available evidence on the efficacy, safety and coverage

Insulin degludec/liraglutide (Xultophy®) Insulin degludec/liraglutide (Xultophy®) Insulin degludec/liraglutide (Xultophy®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Insulin degludec/liraglutide (Xultophy®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC (...) ), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2544. 2015 Authors' conclusions Insulin degludec/liraglutide (Xultophy®) is recommended as an option for restricted use within NHS Wales. Insulin degludec/liraglutide (Xultophy®) is licensed for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a glucagon-like peptide

Guide to Starting and Adjusting Insulin for Type 2 Diabetes Guide to Starting and Adjusting Insulin for Type 2 Diabetes | CADTH.ca Find the information you need Guide to Starting and Adjusting Insulin for Type 2 Diabetes Guide to Starting and Adjusting Insulin for Type 2 Diabetes Published on: July 16, 2012 Result type: Report Adapted from Guide to Starting and Adjusting Insulin for Type 2 Diabetes , ©2008 International Diabetes Center, Minneapolis, MN. All rights reserved. Many people (...) with type 2 diabetes need insulin therapy. A variety of regimens are available. Here are some tips when discussing insulin therapy: 1 Discuss insulin early to change negative perceptions (e.g., how diabetes changes over time; insulin therapy as a normal part of treatment progression). To encourage patient buy-in, it may be more strategic initially to begin with a regimen that will be the most acceptable to the patient even if it may not be the clinician's first choice (e.g., pre-mixed instead of basal

Insulin glargine (Basaglar) Insulin glargine | CADTH.ca Find the information you need Insulin glargine Insulin glargine Last Updated: September 4, 2015 Result type: Reports Project Number: SE0451-000 Product Line: Generic Name: Insulin glargine Brand Name: Basaglar Manufacturer: Eli Lilly Canada Inc. Indications: Diabetes mellitus, Type 1 & 2 Submission Type: New Project Status: Complete Date Recommendation Issued: April 14, 2016 Recommendation Type: List with clinical criteria

Cross-species gene expression analysis identifies a novel set of genes implicated in human insulin sensitivity Insulin resistance (IR) is one of the earliest predictors of type 2 diabetes. However, diagnosis of IR is limited. High fat fed mouse models provide key insights into IR. We hypothesized that early features of IR are associated with persistent changes in gene expression (GE) and endeavored to (a) develop novel methods for improving signal:noise in analysis of human GE using mouse (...) improved diagnosis of IR compared with routine clinical measures across multiple independent data sets. Individuals misclassified by GEM possessed other metabolic features raising the possibility that they represent a separate metabolic subclass. The GEM was enriched in pathways previously implicated in insulin action and revealed novel associations between β-catenin and Jak1 and IR. Functional analyses using small molecule inhibitors showed an important role for these proteins in insulin action.This

Efficacy and Safety of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, as Add-On to Insulin in Patients With Type 1 Diabetes This study assessed the efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in adults with type 1 diabetes.This 18-week, double-blind, phase 2 study randomized 351 patients (HbA1c 7.0-9.0% [53-75 mmol/mol]) on multiple daily insulin injections or continuous subcutaneous insulin infusion to canagliflozin 100 (...) or 300 mg or placebo. The primary end point was the proportion of patients achieving at week 18 both HbA1c reduction from baseline of ≥0.4% (≥4.4 mmol/mol) and no increase in body weight. Other end points included changes in HbA1c, body weight, and insulin dose, as well as hypoglycemia incidence. Safety was assessed by adverse event (AE) reports.More patients had both HbA1c reduction ≥0.4% and no increase in body weight with canagliflozin 100 and 300 mg versus placebo at week 18 (36.9%, 41.4%, 14.5

Insulin degludec/liraglutide: benefit assessment according to §35a Social Code Book V (dossier assessment) Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Insulin degludec/Liraglutid – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 July 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A15-15 (...) Insulin degludec/liraglutide – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A15-15 Version 1.0 Insulin degludec/liraglutide – Benefit assessment acc. to §35a SGB V 30 July 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Insulin degludec/liraglutide – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint

[Insulin degludec (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)] Insulin degludec (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V [Insulin degludec (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)] Insulin degludec (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V [Insulin degludec (new therapeutic indication) - Benefit assessment according to §35a (...) Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Insulin degludec (neues anwendungsgebiet) – nutzenbewertung gemäß § 35a SGB V. [Insulin degludec (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und

[Continuous interstitial glucose monitoring (CGM) with real-time measurement devices in insulin-dependent diabetes mellitus] Kontinuierliche interstitielle glukosemessung (CGM) mit real-time-messgeräten bei insulinpflichtigem diabetes mellitus [Continuous interstitial glucose monitoring (CGM) with real-time measurement devices in insulin-dependent diabetes mellitus] Kontinuierliche interstitielle glukosemessung (CGM) mit real-time-messgeräten bei insulinpflichtigem diabetes mellitus [Continuous (...) interstitial glucose monitoring (CGM) with real-time measurement devices in insulin-dependent diabetes mellitus] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Kontinuierliche interstitielle glukosemessung (CGM) mit real-time-messgeräten bei insulinpflichtigem diabetes mellitus. [Continuous interstitial glucose monitoring (CGM

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial To confirm the superiority, compared with placebo, of adding liraglutide to pre-existing basal insulin analogue ± metformin in adults with inadequately controlled type 2 diabetes [glycated haemoglobin (HbA1c) 7.0-10.0% (53-86 mmol/mol)].In this 26-week, double-blind, parallel-group study, conducted in clinics (...) or hospitals, 451 subjects were randomized 1 : 1 to once-daily liraglutide 1.8 mg (dose escalated from 0.6 and 1.2 mg/day, respectively, for 1 week each; n = 226) or placebo (n = 225) added to their pre-existing basal insulin analogue (≥20 U/day) ± metformin (≥1500 mg/day). After randomization, insulin adjustments above the pre-study dose were not allowed. The primary endpoint was HbA1c change.After 26 weeks, HbA1c decreased more with liraglutide [-1.3% (-14.2 mmol/mol)] than with placebo [-0.1% (-1.2 mmol

Epinephrine versus Glucagon for the Management of Severe Hypoglycemia in Insulin-Dependent Patients: Clinical and Cost-Effectiveness Epinephrine versus Glucagon for the Management of Severe Hypoglycemia in Insulin-Dependent Patients: Clinical and Cost-Effectiveness | CADTH.ca Find the information you need Epinephrine versus Glucagon for the Management of Severe Hypoglycemia in Insulin-Dependent Patients: Clinical and Cost-Effectiveness Epinephrine versus Glucagon for the Management of Severe (...) Hypoglycemia in Insulin-Dependent Patients: Clinical and Cost-Effectiveness Published on: September 30, 2015 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of epinephrine compared with glucagon for the management of severe hypoglycemia in insulin-dependent patients? What is the cost-effectiveness of epinephrine compared with glucagon for the management of severe hypoglycemia in insulin-dependent patients? Key Message

Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial To compare the efficacy and safety of Technosphere insulin (TI) and insulin aspart in patients with type 1 diabetes.This open-label noninferiority trial compared the change in HbA1c from baseline to week 24 of prandial TI (n = 174) with that of subcutaneous aspart (n = 171), both with basal insulin, in patients with type 1 diabetes and HbA1c 7.5-10.0% (56.8-86.0 mmol/mol).Mean (...) (P = 0.0102). TI patients had a lower hypoglycemia event rate than aspart patients (9.8 vs. 14.0 events/patient-month, P < 0.0001). Cough (generally mild) was the most frequent adverse event (31.6% with TI, 2.3% with aspart), leading to discontinuation in 5.7% of patients. Treatment group difference for mean change from baseline in forced expiratory volume in 1 s was small (40 mL) and disappeared upon TI discontinuation.In patients with type 1 diabetes receiving basal insulin, HbA1c reduction